These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 32714765)
21. Activation of invariant natural killer T cells impedes liver regeneration by way of both IFN-γ- and IL-4-dependent mechanisms. Yin S; Wang H; Bertola A; Feng D; Xu MJ; Wang Y; Gao B Hepatology; 2014 Oct; 60(4):1356-66. PubMed ID: 24623351 [TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Berkers CR; Ovaa H Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372 [TBL] [Abstract][Full Text] [Related]
23. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160 [TBL] [Abstract][Full Text] [Related]
27. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d. Yu KO; Im JS; Illarionov PA; Ndonye RM; Howell AR; Besra GS; Porcelli SA J Immunol Methods; 2007 May; 323(1):11-23. PubMed ID: 17442335 [TBL] [Abstract][Full Text] [Related]
28. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15. Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686 [TBL] [Abstract][Full Text] [Related]
29. Ex Vivo ELISpot Assay to Investigate iNKT Cell Responses in Acute Dengue Infection. Kamaladasa AI; Malavige GN Methods Mol Biol; 2018; 1808():181-186. PubMed ID: 29956184 [TBL] [Abstract][Full Text] [Related]
30. Repeated α-GalCer Administration Induces a Type 2 Cytokine-Biased iNKT Cell Response and Exacerbates Atopic Skin Inflammation in Vα14 Park HJ; Kim TC; Park YH; Lee SW; Jeon J; Park SH; Van Kaer L; Hong S Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829848 [TBL] [Abstract][Full Text] [Related]
31. Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. Werter IM; Schneiders FL; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ Oncoimmunology; 2014 Oct; 3(9):e955343. PubMed ID: 25941612 [TBL] [Abstract][Full Text] [Related]
32. Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Ban Y; Dong W; Zhang L; Zhou T; Altiti AS; Ali K; Mootoo DR; Blaho VA; Hla T; Ren Y; Ma X Front Immunol; 2019; 10():404. PubMed ID: 30941120 [No Abstract] [Full Text] [Related]
33. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410 [TBL] [Abstract][Full Text] [Related]
34. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells. Fallarini S; Paoletti T; Panza L; Lombardi G Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950 [TBL] [Abstract][Full Text] [Related]
35. Comparison of 6B11 mAb and α-GalCer-loaded CD1d dextramers for detection of iNKT cells by flow cytometry. Lenart M; Gruca A; Mueck A; Rutkowska-Zapała M; Surman M; Szaflarska A; Kobylarz K; Baran J; Siedlar M J Immunol Methods; 2017 Jul; 446():1-6. PubMed ID: 28365328 [TBL] [Abstract][Full Text] [Related]
36. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432 [TBL] [Abstract][Full Text] [Related]
37. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. Schmieg J; Yang G; Franck RW; Tsuji M J Exp Med; 2003 Dec; 198(11):1631-41. PubMed ID: 14657217 [TBL] [Abstract][Full Text] [Related]
38. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules. Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930 [TBL] [Abstract][Full Text] [Related]
39. Synthesis of 5-Thio-α-GalCer Analogues with Fluorinated Acyl Chain on Lipid Residue and Their Biological Evaluation. He P; Zhao C; Lu J; Zhang Y; Fang M; Du Y ACS Med Chem Lett; 2019 Feb; 10(2):221-225. PubMed ID: 30783507 [TBL] [Abstract][Full Text] [Related]
40. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]